Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPC
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Radiation: IB-positive group
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2021-04-29
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT04745741
- Locations
- 🇨🇳
Department of radiation oncology, Fujian cancer hospital, Fuzhou, Fujian, China
Second-line Surufatinib Combined With Chemotherapy in Advanced CRC
Phase 2
- Conditions
- Advanced Colorectal Cancer
- Interventions
- Drug: Surufatinib(HMPL-012)
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 56
- Registration Number
- NCT04734249
Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04613804
- Locations
- 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China
Opioid Titration With 12.5 ug/h Fentanyl Transdermal Patch vs Orally Morphine for Opioid-naïve Patients With Moderate Cancer Pain
Phase 3
- Conditions
- Opioid, Moderate Cancer Pain, Transdermal Fentanyl, 12.5ug/h, Opioid-naive
- Interventions
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 209
- Registration Number
- NCT04533243
Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC
Phase 2
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Drug: Triprilimab(JS001)
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT04421469
- Locations
- 🇨🇳
Department of radiation oncology, Fujian cancer hospital, Fuzhou, Fujian, China
To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC
Completed
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Radiation: modified reduce-volume target IMRT
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2020-10-09
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 471
- Registration Number
- NCT04387266
- Locations
- 🇨🇳
Department of radiation oncology, Fujian cancer hospital, Fuzhou, Fujian, China
Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 13
- Registration Number
- NCT04354961
- Locations
- 🇨🇳
Beijing Chest Hospital, Capital Medical University, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
Phase 2
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Drug: Capecitabine/S-1Drug: ChemotherapyRadiation: Head and neck radiotherapyOther: Local Consolidative Therapy
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT04319471
- Locations
- 🇨🇳
Department of radiation oncology, Fujian cancer hospital, Fuzhou, Fujian, China
Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful Titration
Phase 2
Completed
- Conditions
- Cancer Pain
- Interventions
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 95
- Registration Number
- NCT04243954
- Locations
- 🇨🇳
China, Fujian, Fuzhou, Fujian, China
Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC
Phase 2
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Drug: Capecitabine/Tiggio
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 129
- Registration Number
- NCT04220528
- Locations
- 🇨🇳
Department of radiation oncology, Fujian cancer hospital, Fuzhou, Fujian, China
© Copyright 2025. All Rights Reserved by MedPath